Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Adaptive, Phase III trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum (IRX1001/IFX-1-P3-4)

This study seeks persons with ulcerative pyoderma gangrenosum to find out if a new investigational drug, vilobelimab is safe and effective in treating the condition.

Seeking: Persons diagnosed with Ulcerative Pyoderma Gangrenosum.

PI. Dr. Naveed Sami, MD